Member Info for Bibio

Will Scancell likely maintain a listing on AIM . . . . . or has PLH had enough ?

Good spot Cleaner world . . . . .

https://www.gov.uk/government/news/unique-liaison-programme-set-to-reinforce-close-collaboration-between-mhra-and-fda

A good opportunity to ask some searching questions . . . along the lines of :

1. Do you envisage resurrecting the collaboration with Solaris Healthcare/MidLantic prior to reaching break even & if not why not ?

2. How many big Pharma are CellbxHealth still talking to? Has it increased or decreased since the reorganisation & can you provide an idea of how many there are?

3. Do Cellbxhealth still co-market Parsortix with Illumina ?

Etc. . . . .

"Rather than funding a single specific trial, the MSA agreement allows any global team within AstraZeneca's drug discovery and oncology R&D pipeline to directly commission CelLBxHealth's services on an as-needed basis.

Revenue Generation: Income will be realized progressively over time as AstraZeneca triggers individual work orders for specific clinical trial sample batches.

Broader Commercial Impact

Market Validation: The primary immediate value is institutional credibility.

Support for 2026 Revenue Goals:

While the contract lacks a single headline figure, management cited agreements of this calibre as core pillars supporting their corporate target."

AstraZeneca are running over 100 phase III oncology trials, 19 phase II trials & 20 phase I trials.

It is unlikely to be long before CTC analysis becomes standard protocol for each & every AstraZeneca research group, globally.

"It is highly likely Roche will expand its relationship with CelLBxHealth (formerly known as ANGLE). However, rather than an identical master services agreement, Roche's approach will likely be grounded in the clinical development of diagnostics and automated workflows rather than just outsourced drug development.

Here is how the dynamics set the stage for a Roche agreement:

The Precedent (AstraZeneca)The Deal: In May 2026, CelLBxHealth signed a Master Services Agreement to provide circulating tumour cell (CTC) analytics across AstraZeneca's drug discovery and clinical development pipeline using the Parsortix platform.

The Goal: To utilize "liquid biopsies" (blood tests) to identify how tumours respond to treatment, allowing for rapid, non-invasive real-time cancer monitoring.

The Roche Connection Automated Workflow Compatibility: Unlike AstraZeneca's pure service-based agreement, CelLBxHealth successfully demonstrated proof-of-concept. The Parsortix system was shown to be fully compatible with Roche's globally standardized BenchMark ULTRA automated staining platform.

Targeting Cancer: The joint workflow has already been successfully tested on key Antibody-Drug Conjugate (ADC) biomarkers:HER2 (Breast cancer)TROP2 (Lung cancer)PSMA (Prostate cancer).

Why an Expansion with Roche is Expected

Diagnostic Leadership:

Roche is the largest global player in the tissue-testing market. Automating Parsortix CTCs through Roche's BenchMark systems bridges the gap between liquid biopsies and traditional pathology labs.

Focus on ADCs: Roche is heavily invested in oncology therapies, particularly ADCs. Combining CelLBxHealth's Parsortix platform with Roche's market-dominating diagnostic hardware provides a streamlined method to determine exactly which patients will respond to these advanced drugs."

A welcome change from the ramp brigade . . . . 🙄

"AstraZeneca is currently using the Parsortix platform across a broad but unquantified number of trials.

Rather than operating in a set number of trials, the platform is broadly deployed across AstraZeneca's development pipeline.

AstraZeneca uses Parsortix technology, which is developed by CelLBxHealth (formerly ANGLE), for two main clinical applications:

Androgen Receptor (AR) Assays:

Used for prostate cancer studies & clinical activity related to AR therapies tracked across more than 130 active clinical trials with 30,000 participants.

DNA Damage Response (DDR) Micronuclei Assays:

Used to detect treatment-related DNA damage across multiple cancer types. There are approximately 133 DDR-related clinical trials encompassing over 16,000 patients.

In late May 2026, AstraZeneca expanded this relationship by entering into a Master Services Agreement with CelLBxHealth to provide CTC-powered analytics across their entire oncology development pipeline."

An Ai view 🤔

More air being pumped here than a BP service station - give it a rest for heavens sake . . . . . same 💩 different day.

"Biotech M&A is broken. The historical playbook was simple: a startup creates an incredible asset, and a multinational pharma company (MNC) swallows them whole to run the commercial launch. But the top-tier biotechs are now refusing to be acquired—and they are poaching Big Pharma's crown jewels to build their own global empires.

Earlier this year, Merck ($MRK) offered a massive $32B to acquire Revolution Medicines ($RVMD) for their pan-RAS oncology pipeline. Revolution flatly rejected the buyout.

Now, the story gets wild. Not only did Revolution refuse the acquisition, but they just poached Thomas Lampron—Merck’s Global VP of Oncology Marketing and one of the core architects behind Keytruda’s historic commercial scale-up.

The move signals that the pan-RAS field is officially transitioning from an early-stage science story into aggressive commercial execution. At ASCO 2026, Revolution's lead asset daraxonrasib demonstrated a median Overall Survival (mOS) of 13.2 months vs 6.7 months for chemotherapy in pancreatic cancer—effectively doubling survival in a historical regulatory graveyard.

Instead of passing the baton to an MNC, Revolution is keeping the economics and assembling a heavy-hitting commercial team to launch daraxonrasib independently. For Merck, losing the acquisition target was a strategic setback; losing their elite oncology marketing talent to that same target is a brutal validation of changing power dynamics.

This is the pipeline to watch. "

https://x.com/i/status/2062957638808399877

Whether Scancell are on their way to qualifying as a top tier Biotech - time will tell. The clock is now ticking that much louder with questions due to be answered in the not too distant future . . . . .

Upcoming notable conferences and summits dedicated to the liquid biopsy field include:

5th Liquid Biopsy for Precision Oncology Summit East Coast: Held in Boston, MA, USA from July 20–22, 2026.

Cancer & Oncology Conference 2026 (Liquid Biopsy track): Held in Prague, Czech Republic from July 23–24, 2026.

The EACR Liquid Biopsies 2026 conference takes place in Lyon, France, from September 22–24,

ELBS Annual General Assembly 2026 (European Liquid Biopsy Society): Held in Uppsala, Sweden from November 9–10, 2026.

The ISLB 2026 Annual Congress (International Society of Liquid Biopsy). It will be held in Madrid, Spain, from November 7–9, 2026.

Updates don't get much better than the AstraZeneca MSA but the Halo effect is most likely to take affect at any one of the above noted conferences . . . . .

HAGW

Thanks for sharing Workbench . . . . .

Undervalued & EmeraldCarrots on filter.

& smacking of desperation while being counter productive.

Https://x.com/i/status/2060823812115935415

"Immatics is utilising Cellbxhealth’s (ANGLE plc) Parsortix circulating tumor cell (CTC) enrichment system across three clinical trials. This technology is specifically employed to capture and analyze intact live cancer cells from blood samples for the following core studies:

Melanoma Phase 3 Trial:

The services agreement includes Parsortix enrichment for a Phase 3 study evaluating Immatics’ T-cell receptor (TCR-T) cell therapies (such as their lead candidate IMA203 for PRAME-expressing solid tumors).

Two Additional Solid Tumor Trials: The technology is running across two other early-stage trials assessing Immatics’ adoptive cell therapies and targeted bispecifics.The Parsortix system allows Immatics to isolate live CTCs to gather translational data, guiding and monitoring the efficacy of highly personalized immunotherapies.

You can track the full trial portfolio on the Immatics Clinical Trials page."

Just out of ASCO 2026

https://x.com/i/status/2060811474340081813"

Given the amount of industry wide talk about CTC's (also mentioned by the CEO) if a takeover move was initiated prior to subsequent MSA's being signed etc & prior to reaching breakeven then it may very well be hostile.

There are many PI shareholders that will have a significantly higher average than this currently low share price. I suspect they will view a takeover move with mixed feelings if it were to happen too soon.

I agree though that the BoD are a commercial step up from the pioneering previous BoD.

It'll all come out in the wash but hopefully not to soon.

"CelLBxHealth (formerly ANGLE plc) is an increasingly attractive takeover target for major life science and diagnostic companies.

Following a massive £6.6 million restructuring, the Guildford-based firm offers a highly sought-after liquid biopsy platform, significant clinical validation, and highly scalable commercial operations at an opportunistic market valuation.

Key Takeover Appeal:

Cutting-Edge CTC Technology: CelLBxHealth’s patent-protected Parsortix platform harvests circulating tumour cells (CTCs) from blood samples, allowing for whole-cell imaging and proteomic profiling that traditional tissue biopsies or ctDNA simply cannot provide.

Big Pharma Validation:

The company recently secured a master services agreement with AstraZeneca, establishing CelLBxHealth as a qualified service provider across the drug-discovery pipeline.

Premier Clinical Partnerships:

CelLBxHealth is running major trials with high-profile institutions, including a 200-patient study with The Royal Marsden and the ACTION and SUNRISE studies with US-based AdventHealth.

Lean, Streamlined Cost Base:

Under Executive Chairman Dr. Jan Groen and CEO Peter Collins, the company slashed headcount and streamlined operations, positioning the business to focus directly on product sales, laboratory services, and laboratory-developed tests (LDTs)."

CelLBx Health appear to be under starters orders in the race to break-even/profitability before a takeover (hostile) is mounted. The new look BoD appear to have hit the ground running but those inflection points alluded to by Peter Collins are key.

"Liquid biopsy is highly prominent at ASCO 2026, anchoring multiple Special Clinical Science Symposia and overarching the conference's precision oncology tracks. While the spotlight is heavily on cell-free DNA (ctDNA) and minimal residual disease (MRD), Circulating Tumor Cells (CTCs) are prominently featured as vital, complementary dynamic biomarkers.Key Highlights & TrendsMajor Symposia: The clinical utility of ctDNA and blood-based biomarkers acts as a core focus, including dedicated Special Clinical Science Symposia and Education Sessions exploring how to best interpret liquid biopsy results in routine clinical practice.CTCs as Prognostic Tools: CTC presence and counts continue to be central to prognostic stratification. For example, data presented at the meeting on advanced breast cancer demonstrated how combining CTC subtypes with other assays (like CAMLs) can significantly enhance patient risk-stratification and predict treatment responses.Multimodal Approaches: Researchers are moving past single-platform tests. Prominent presentations focus on integrating CTCs, ctDNA, and tissue biopsies to provide a highly holistic view of a patient's tumor biology and resistance mechanisms.Cellular Residual Disease (CRD): There is growing scientific excitement regarding the role of CTCs and circulating tumor microemboli (CTMs) in early MRD detection, with studies highlighting combinational indices (like the P-score) for more accurate, longitudinal lung cancer monitoring.Global Push: Liquid biopsy is also a primary focus at the ASCO Breakthrough meeting, with new studies highlighting its performance in early cancer detection and recurrence tracking across varying global populations.To explore the exact abstracts and session schedules, you can use the ASCO Annual Meeting Program. For a broader scope of the technology's integration into global healthcare, refer to the ASCO Breakthrough Meeting announcements."

Peter Collins was preparing for ASCO well in advance.

Servalan - completely agree . . . . looks like desperation from "undervalued" & the slavishly boring "Emeraldcarrots".

Not a huge surprise that CelLBx Health waited til today to announce the MSA - as posted at the beginning of the week Peter Collins was attending ASCO which starts today in the US. The world's largest & most prestigious Oncology conference . . . . . .

Good find Workbench1.3 & a welcome change from the endless repeat posting & ramping from two on this BB.